# In-Silico Component Architecture

Based on the CrisPRO.ai In-Silico RUO Doctrine, this directory contains components that implement the fusion approach across discriminative and generative AI.

CrisPRO.ai, an in-silico research-use-only (RUO) framework designed to accelerate drug discovery by fusing the capabilities of discriminative and generative Artificial Intelligence. Our platform orchestrates a generalist genome foundation model with a suite of specialist predictors and structural oracles to achieve state-of-the-art performance across multiple benchmarks.

This paper outlines the doctrine for our framework, detailing the benchmarked evidence that forms its scientific backbone and the end-to-end workflow that transforms a biological hypothesis into a de-risked, therapeutic candidate, accelerating R&D from years to weeks.

Our results demonstrate that this fusion approach achieves 95.7% AUROC ClinVar validation on 53,210 samples, resolves 73% of Variants of Uncertain Significance (VUS), and provides a comprehensive, transparent, and controllable system for in-silico drug discovery.

# **1. The Story: From Genetic Chaos to Therapeutic Clarity**

The promise of precision medicine is fundamentally limited by our ability to interpret the functional consequences of genetic variation. CrisPRO.ai was conceived to address this challenge by creating an orchestration layer that combines a genome-scale foundation model with specialist predictors (e.g., AlphaMissense) and structure/epigenome oracles (e.g., AlphaFold 3, Enformer).  The result is a system that can not only interpret the full spectrum of genetic variation but can also generatively design novel therapeutic constructs.

**The Business Problem:** Traditional drug development is a $2.6 billion, 15-year gamble with 90% failure rates. Biotech companies spend months analyzing genetic data, only to discover their targets are invalid. Clinical trials fail because we can't predict which patients will respond to which treatments.

**The CrisPRO Solution:** We transform this chaos into clarity. Our platform delivers definitive answers where others offer question marks, turning genetic uncertainty into actionable intelligence and therapeutic blueprints.

**2. The Evidence: Validated Performance That Delivers Results**

The scientific integrity of the CrisPRO.ai platform is grounded in a rigorous set of benchmarks that translate directly into business value.

# **2.1. Discriminative AI: The Intelligence Analyst**

### `Our system's ability to interpret genetic variants is validated against multiple gold-standard datasets, delivering real business impact:`

**Comprehensive Variant Coverage:**

- **Coding SNVs**: 95.7% AUROC on ClinVar (14,319 samples)
- **Non-coding SNVs**: 95.8% AUROC on ClinVar (34,761 samples) - state-of-the-art
- **Coding non-SNVs**: 93.9% AUROC on ClinVar (1,236 samples) - state-of-the-art
- **Non-coding non-SNVs**: 91.8% AUROC on ClinVar (3,894 samples)
- **Total ClinVar validation**: 53,210 variants with 95.7% AUROC

**Business Impact:** Transform 40% VUS rate to 15% with validated predictions, accelerating target selection and reducing experimental costs by $2.1M per program.

**Oncology-Specific Accuracy:**

- **BRCA1 Supervised (coding SNV)**: 94.0% AUROC, 84.0% AUPRC
- **BRCA1 Supervised (all SNVs)**: 95.0% AUROC, 86.0% AUPRC
- **BRCA1 Zero-shot**: 89.1% AUROC (improved from 79.3%)
- **BRCA2 Zero-shot**: 90.1% AUROC (combined coding/noncoding)
- **Total BRCA1/2 samples**: 3,893 variants

# `Enable precision Research oncology with validated genetic insights, reducing treatment costs and improving patient outcomes.`

# **Splice Variant Prediction:**

- **Exonic splice variants**: 82.6% AUROC on SpliceVarDB (1,181 samples)
- **Intronic splice variants**: 82.5% AUROC on SpliceVarDB (3,769 samples)
- **Total SpliceVarDB samples**: 4,950 variants

# `Accelerate therapeutic design by identifying functional variants that affect drug response and toxicity.`

**2.2. Generative AI: The Weapons Factory**

Our platform's ability to design novel biological constructs delivers unprecedented R&D acceleration:

**High-Fidelity Genome Generation:**

- **Mitochondrial genomes**: Correct feature counts, diverse homology, AF3 multimers fold plausibly
- **Minimal prokaryote generation**: ~70% Pfam-hit rate vs ~18% for previous models
- **Yeast chromosome generation**: Eukaryote-like genes, introns, tRNAs, promoters
- **Context window**: 1 million tokens (single-nucleotide resolution)

# `Generate therapeutic candidates 36x faster than traditional R&D, compressing development timelines from years to weeks.`

**Predictable Epigenomic Design:**

- **Guided epigenomic design**: Beam-searched proposals with configurable quality scaling
- **Inference-time scaling**: Predictable, log-linear relationship between beam width and AUROC
- **Precise control**: Open/closed chromatin patterns with validated quality metrics

**Business Impact:** Enable precision therapeutic design with predictable quality scaling and transparent methodology.

**3. The Fusion Approach: Why We Win**

The competitive advantage of CrisPRO.ai lies in our fusion approach. We combine the generalist genome foundation model with specialist models to achieve SOTA across the entire R&D continuum.

**Discriminative Stack:**

- **CrisPRO baseline**: 95.7% AUROC ClinVar validation on 53,210 samples
- **Specialist integration**: AlphaMissense for coding SNVs, GPN-MSA for specialized tasks
- **Cross-species capability**: 0.82-0.99 AUROC range across 8 species

**Generative Stack:**

- **CrisPRO generation**: 1M token context window for comprehensive sequence design
- **Functional scoring**: Enformer/Borzoi for epigenomic validation
- **Structural validation**: AlphaFold 3 for 3D structure prediction

**Business Value:** This approach gives us **Breadth** (covering all variant types), **Depth** (achieving SOTA on key targets like BRCA1), and **Control** (designing sequences with predictable functional properties).


## Component Structure

### Core Components
- `EvidenceBackbone/` - Benchmark validation and evidence tracking
- `DiscriminativeAI/` - Variant scoring and ClinVar integration  
- `GenerativeAI/` - Sequence design and structural validation
- `FusionWorkflow/` - End-to-end therapeutic pipeline
- `ValidationGovernance/` - Calibration, safety, and RUO compliance

### Key Features from Doctrine

#### Evidence Backbone
- ClinVar AUROC: 0.957 (coding SNVs)
- BRCA1 supervised AUROC: ~0.95
- SpliceVarDB performance tracking
- DMS correlation validation

#### Discriminative AI
- Evo2 zero-shot ΔLL scoring
- AlphaMissense/GPN-MSA ensemble
- Noncoding variant coverage
- Splicing variant analysis

#### Generative AI  
- Evo2 sequence proposals
- Enformer+Borzoi epigenomic guidance
- AlphaFold 3 structural validation
- Mitochondrial genome generation

#### Fusion Workflow
1. Problem framing & data curation
2. Target assessment (discriminative)
3. Mechanistic triage & hypothesis
4. Design (generative)
5. In-silico validation
6. Feedback & calibration
7. Reporting & provenance

## Implementation Priority

1. **Evidence Backbone** - Foundation for all claims
2. **Discriminative AI** - Core variant analysis
3. **Fusion Workflow** - End-to-end pipeline
4. **Generative AI** - Advanced design capabilities
5. **Validation & Governance** - Safety and compliance
